A landmark study of gender medicine is caught in an ethics row


A review of transgender medicine by Hilary Cass reveals weak scientific evidence supporting the use of puberty blockers and cross-sex hormones in teenagers, sparking an ethics debate.
AI Summary available — skim the key points instantly. Show AI Generated Summary
Show AI Generated Summary

ONE REASON that transgender medicine is such a fraught topic is that there is little evidence behind the arguments. When Hilary Cass, a British paediatrician, reviewed the field for an influential report published in 2024, she noted that most of the science underlying the prescription of puberty blockers and cross-sex hormones to teenagers (an approach called “gender-affirming care”) was “remarkably weak”.

🧠 Pro Tip

Skip the extension — just come straight here.

We’ve built a fast, permanent tool you can bookmark and use anytime.

Go To Paywall Unblock Tool
Sign up for a free account and get the following:
  • Save articles and sync them across your devices
  • Get a digest of the latest premium articles in your inbox twice a week, personalized to you (Coming soon).
  • Get access to our AI features

  • Save articles to reading lists
    and access them on any device
    If you found this app useful,
    Please consider supporting us.
    Thank you!

    Save articles to reading lists
    and access them on any device
    If you found this app useful,
    Please consider supporting us.
    Thank you!